Phase 1
Safety, PK, Early PD
Early human studies produce noise before they deliver clarity. Signals are faint, confounders are everywhere, and timelines are unforgiving. Phase 1 requires analytics that can reveal patterns and relevance without losing the confidence of clinical teams.
What companies need at this stage
Teams require clean QC, early PD biomarkers, and rigorous modeling of confounders. They also need fast integration of clinical and molecular data to guide dose decisions and prepare Phase 2 with evidence.
BioLizard solutions
- QC and standardized pipelines.
- Mixed-effects models for biomarker interpretation.
- Confounder correction for batch, run, and site effects.
- Early MoA insights from integrated multi-omics.
- Clinical dashboards that help teams examine signals in real time.
Relevant Bio|Verse® modules
Bio|Verse® provides compliant infrastructure, traceability, and interactive views of biomarker trends and patient-level data for your clinical studies.
Explore →
Modular offerings
Clinical omics QC | Exploratory PD biomarker frameworks | Integrated transcriptomics and proteomics packages | Batch and technical correction modules
Explore all solutions →
Converting genetic resistance into metabolic yield
Salmonella infection in poultry has a detrimental effect on growth and therefore production. Knowledge of host resistance genes helps optimize precision management.
Omics-driven diagnostics in animals
Chronic diseases are a burden for companion animals, but can be managed better if diagnosed early. Multi-omics analysis is complex, but offers opportunities to discover novel biomarker panels.
Exploring target expression and identifying other indications with a similar mode of action
The client wanted to study the expression of their target gene within two known indications and to uncover other diseases where the target has a similar mode of action. Identifying comparable indications could strengthen the business case for further development. Our...